Seres Therapeutics SER-155 Shows Potential In Transplant Care

Seres Therapeutics, Inc., a lead in live biotherapeutics, has shared encouraging new translational biomarker findings from its Phase 1b placebo-controlled study of SER-155. This study was performed in patients undergoing allogeneic stem cell transplantation (allo-HSCT). The data revealed a significant reduction in faecal albumin levels, an established marker of gut barrier integrity following SER-155 treatment, along with improvements in systemic inflammation and immune balance compared to placebo. 

Wendy Garrett, M.D. Ph.D., Professor of Immunology and Infectious Diseases, Department of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, stated, “The SER-155 translational biomarker data, combined with the promising clinical results demonstrating an impressive reduction in bloodstream infection rates, provide strong biological evidence supporting Seres’ live biotherapeutic candidates as a novel potential therapeutic approach to improve epithelial barrier integrity and to positively modulate multiple inflammatory pathways. These data support potential opportunities for live biotherapeutics, beyond infection, in inflammatory and immune diseases."

These outcomes reflect the previous clinical data indicating that SER-155 experimentation reduced bloodstream infections (BSIs) by 77% in relative risk. The data demonstrate the potential of SER-155 to improve gut barrier function and address the harmful bacteria migrating from the gastrointestinal tract into the bloodstream. 

The decrease in inflammatory indexes and change in the immune system ratios bring even more interest in SER-155 among allo-HSCT patients. Apart from the allo-HSCT, these outcomes support the prospects for Seres’ live biotherapeutic platform for other inflammatory and immune-related states, including IBD, such as ulcerative colitis and Crohn’s disease.